Bezlotoxumab reduces odds of recurrent C. difficile infection in transplant recipients
Bezlotoxumab significantly reduced the incidence of recurrent Clostridioides difficile infection among solid-organ transplant and hematopoietic-cell transplant recipients, according to a study published in Open Forum Infectious Diseases.“Solid-organ and hematopoietic-cell transplant recipients are at high-risk for recurrent Clostridioides difficile infection and poor outcomes associated